Phase II Clinical Trial of Sipatrigine (619C89) by Continuous Infusion in Acute Stroke

Publisher： Karger

E-ISSN： 1421-9786|10|6|431-436

ISSN： 1015-9770

Source： Cerebrovascular Diseases, Vol.10, Iss.6, 2000-10, pp. : 431-436

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Safety and Tolerability of 619C89 after Acute Stroke

By  

Cerebrovascular Diseases, Vol. 8, Iss. 1, 1998-01 ,pp. : 31-37

Karger

Access to resources Recommend Favorite

Glycine Antagonist (GV150526) in Acute Stroke: A Multicentre, Double-Blind Placebo-Controlled Phase II Trial

By  

Cerebrovascular Diseases, Vol. 11, Iss. 1, 2001-01 ,pp. : 20-29

Karger

Access to resources Recommend Favorite

Fiblast (Trafermin) in Acute Stroke: Results of the European-Australian Phase II/III Safety and Efficacy Trial

By  

Cerebrovascular Diseases, Vol. 14, Iss. 3-4, 2002-10 ,pp. : 239-251

Karger

Access to resources Recommend Favorite

Poster Session II: Acute Stroke (Clinical Physiology)

By  

Cerebrovascular Diseases, Vol. 9, Iss. 1, 1999-03 ,pp. : 94-98

Karger

Access to resources Recommend Favorite

Outcome Analysis in Clinical Trial Design for Acute Stroke: Physicians’ Attitudes and Choices

By  

Cerebrovascular Diseases, Vol. 26, Iss. 2, 2008-06 ,pp. : 156-162

Karger

Access to resources Recommend Favorite